臨床外科66巻11号

2011年10月発行

特集 外科医のための最新癌薬物療法 Ⅰ章 臓器別薬物療法

2．肺癌―③進行・再発（切除不能を含む）治療

著者： 大熊裕介¹ 細見幸生¹

所属機関： ¹がん・感染症センター都立駒込病院呼吸器内科

ページ範囲：P.66 - P.85

レジメン選択のアルゴリズム

レジメン選択のアルゴリズム

　小細胞肺癌および進行・再発（切除不能を含む）非小細胞肺癌の治療は，日本肺癌学会編集「肺癌診療ガイドライン」に則り，以下のアルゴリズム（図1～3）のように肺癌患者の年齢・病期・全身状態・組織型・EGFR遺伝子変異の有無に応じた治療法を選択する．

　非小細胞肺癌における切除不能の局所進行期（ⅢA-B期）の治療および限局型小細胞肺癌の治療については，全身状態が良好であれば化学放射線療法が推奨されるが，基本的には内科・放射線治療医が中心となって行うべきであり，本稿では割愛する．

参考文献

1）Azzoli CG, et al：American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage Ⅳ non-small-cell lung cancer. J Clin Oncol 27：6251-6266, 2009

2）Non-small Cell Lung Cancer Collaborative Group：Chemotherapy in non-small cell lung cancer：a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311：899-909, 1995

3）D'Addario G, et al：Metastatic non-small-cell lung cancer：ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21：v116-119（Suppl 5）, 2010

4）Temel JS, et al：Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363：733-742, 2010

5）Furuse K, et al：Early phase Ⅱ study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. Int J Clin Oncol 6：236-241, 2001

6）Kawahara M, et al：Phase Ⅱ study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85：939-943, 2001

7）Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 91：66-72, 1999

8）Frasci G, et al：Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18：2529-2536, 2000

9）Gridelli C, et al：Chemotherapy for elderly patients with advanced non-small-cell lung cancer：the Multicenter Italian Lung Cancer in the Elderly Study（MILES）phase Ⅲ randomized trial. J Natl Cancer Inst 95：362-372, 2003

10）Kudoh S, et al：Phase Ⅲ study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer：results of the West Japan Thoracic Oncology Group Trial（WJTOG 9904）. J Clin Oncol 24：3657-3663, 2006

11）Quoix e, et al：Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer：IFCT-0501 randomised, phase 3 trial. Lancet, in press, doi 10.1016/S0140-6736（11）60780-0, 2011

12）Inoue A, et al：First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27：1394-1400, 2009

13）Minegishi Y, et al：First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations：Multicenter phase Ⅱ trial（NEJ 003 study）. ASCO Meeting Abstracts, No. 7561, 2010

14）Barlsei F, et al：Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer（NSCLC）with asymptomatic inoperable brain metastases：a multicenter phase Ⅱtrial（GFPC07-01）. Ann Oncol, in press , doi 10.1093/annonc/mdr003, 2011

15）Coleman RE：Metastatic bone disease：clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27：165-176, 2001

16）Murray N, Turrisi AT 3rd：A review of first-line treatment for small-cell lung cancer. J Thorac Oncol 1：270-278, 2006

17）Giaccone G, et al：Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 23：1697-1699, 1987

18）Postmus PE, et al：Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 23：1409-1411, 1987

19）Inoue A, et al：Randomized phase Ⅱ trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer：North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 26：5401-5406, 2008

20）Onoda S, et al：Phase Ⅱ trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer：Thoracic Oncology Research Group Study 0301. J Clin Oncol 24：5448-5453, 2006

21）Jotte R, et al：Randomized phase Ⅲ trial of amrubicin versus topotecan（Topo）as second-line treatment for small cell lung cancer（SCLC）. ASCO Meeting Abstracts, No. 7000, 2011

22）Groen HJ, et al：Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide：a non-cross-resistant schedule. J Clin Oncol 17：927-932, 1999

23）Schiller JH, et al：Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346：92-98, 2002

24）Kelly K, et al：Randomized phase Ⅲ trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer：a Southwest Oncology Group trial. J Clin Oncol 19：3210-3218, 2001

25）Ohe Y, et al：Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer：Four-Arm Cooperative Study in Japan. Ann Oncol 18：317-323, 2007

26）Fossella F, et al：Randomized, multinational, phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer：the TAX 326 study group. J Clin Oncol 21：3016-3024, 2003

27）Scagliotti GV, et al：Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26：3543-3551, 2008

28）Hotta K, et al：Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22：3852-3859, 2004

29）Scagliotti G, et al：The differential efficacy of pemetrexed according to NSCLC histology：a review of two Phase Ⅲ studies. Oncologist 14：253-263, 2009

30）Nagel S, et al：Randomized phase Ⅱ study of pemetrexed in combination with cisplatin or carboplatin as first-line chemotherapy in advanced non-small cell lung cancer. ASCO Meeting Abstracts, No. 7628, 2010

31）Kubota K, et al：Phase Ⅲ randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage Ⅳ non-small-cell lung cancer：the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22：254-261, 2004

32）Sandler A, et al：Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355：2542-2550, 2006

33）Nishio M, et al：Randomized, open-label, multicenter phase Ⅱ study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer（NSCLC）：JO19907. ASCO Meeting Abstracts, No. 8036, 2009

34）Reck M, et al：Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer：AVAL. J Clin Oncol 27：1227-1234, 2009

35）Okamoto I, et al：Phase Ⅲ trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer：results of a west Japan oncology group study. J Clin Oncol 28：5240-5246, 2010

36）Mok TS, et al：Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361：947-957, 2009

37）Maemondo M, et al：Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362：2380-2388, 2010

38）Mitsudomi T, et al：Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor（WJTOG3405）：an open label, randomised phase 3 trial. Lancet Oncol 11：121-128, 2009

39）Rosell R, et al：Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361：958-967, 2009

40）Rosell R, et al：Erlotinib versus chemotherapy （CT）in advanced non-small cell lung cancer（NSCLC）patients（P）with epidermal growth factor receptor（EGFR）mutations：Interim results of the European Erlotinib Versus Chemotherapy（EURTAC）phase Ⅲ randomized trial. ASCO Meeting Abstracts, No. 7503, 2011

41）Paz-Ares L, et al：Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations：pooled analysis. J Cell Mol Med 14：51-69, 2010

42）Fidias PM, et al：Phase Ⅲ study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27：591-598, 2009

43）Ciuleanu T, et al：Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer：a randomised, double-blind, phase 3 study. Lancet 374：1432-1440, 2009

44）Cappuzzo F, et al：Erlotinib as maintenance treatment in advanced non-small-cell lung cancer：a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11：521-529, 2010

45）Paz-Ares LG, et al：PARAMOUNT：Phase Ⅲ study of maintenance pemetrexed（pem）plus best supportive care（BSC）versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer（NSCLC）.ASCO Meeting Abstracts, No. 7510, 2011

46）Shepherd FA, et al：Docetaxel（Taxotere）shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer：a review of two phase Ⅲ trials. Semin Oncol 28：4-9, 2001

47）Fossella FV, et al：Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18：2354-2362, 2000

49）Chen JP, et al：Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers. Lung Cancer 60：92-97, 2008

50）Hanna N, et al：Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22：1589-1597, 2004

51）Thatcher N, et al：Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer：results from a randomised, placebo-controlled, multicentre study（Iressa Survival Evaluation in Lung Cancer）. Lancet 366：1527-1537, 2005

52）Shepherd FA, et al：Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353：123-132, 2005

53）Ciuleanu T, et al：LBOA5- Erlotinib versus docetaxel or pemetrexed as second-line therapy in patients with advanced non-small-cell lung cancer（NSCLC）and poor prognosis：efficacy and safety results from the phase Ⅲ TITAN study. 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology Abstract, 2010

54）Mascaux C, et al：A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30：23-36, 2000

55）Noda K, et al：Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346：85-91, 2002

56）Lara PN, Jr, et al：Phase Ⅲ trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer：clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27：2530-2535, 2009

57）Okamoto H, et al：Randomised phase Ⅲ trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer：JCOG 9702. Br J Cancer 97：162-169, 2007